Increased fat mass, decreased myofiber size, and a shift to glycolytic muscle metabolism in adolescent male transgenic mice overexpressing IGFBP-2.
To elucidate the functional role of insulin-like growth factor (IGF)-binding protein-2 (IGFBP-2) for in vivo skeletal muscle growth and function, skeletal muscle cellularity and metabolism, expression of signal molecules, and body growth and composition were studied in a transgenic mouse model overexpressing IGFBP-2. Postnatal growth rate of transgenic mice was reduced from day 21 of age by 6-8% compared with nontransgenic controls. At 10 wk of age body lean protein and moisture percentages were lower, whereas fat percentage was higher in IGFBP-2 transgenic mice. Muscle weights were reduced (-13% on day 30 of age, -14% on day 72), which resulted from slower growth of myofibers in size but not from decreases in myofiber number. The reduction in muscle mass was associated with lower total DNA, RNA, and protein contents as well as greater DNA/RNA and protein/RNA ratios. The percentage of proliferating (Ki-67-positive) nuclei within myofibers was reduced (3.4 vs. 5.8%) in 30-day-old transgenic mice. These changes were accompanied by slight reductions in specific p44/42 MAPK activity (-18% on day 72) and, surprisingly, by increased levels of phosphorylated Akt (Ser(473)) (+25% on day 30, +66% on day 72). The proportion of white glycolytic fibers (55.9 vs. 53.5%) and the activity of lactate dehydrogenase (+8%) were elevated in 72-day-old transgenic mice. Most of the differences observed between transgenic and nontransgenic mice were more pronounced in males. The results suggest that IGFBP-2 significantly inhibits postnatal skeletal myofiber growth by decreasing myogenic proliferation and protein accretion and enhances glycolytic muscle metabolism.
Rehfeldt
Charlotte
C
Research Divisions-Muscle Biology and Growth, Leibniz Institute for Farm Animal Biology, Wilhelm-Stahl-Allee 2, Dummerstorf, Germany. rehfeldt@fbn-dummerstorf.de
Renne
Ulla
U
Sawitzky
Mandy
M
Binder
Gerhard
G
Hoeflich
Andreas
A
D000273:Adipose Tissue / Q000502:physiology*; D000818:Animals; D017209:Apoptosis / Q000502:physiology; D015153:Blotting, Western; D001823:Body Composition / Q000502:physiology; D001835:Body Weight / Q000502:physiology; D002196:Capillaries / Q000502:physiology; D002452:Cell Count; D003402:Creatine Kinase / Q000378:metabolism; D004247:DNA / Q000096:biosynthesis / Q000235:genetics; D004591:Electrophoresis, Polyacrylamide Gel; D006019:Glycolysis / Q000502:physiology*; D006128:Growth / Q000502:physiology; D007150:Immunohistochemistry; D047468:Immunoprecipitation; D018971:Insulin-Like Growth Factor Binding Protein 2 / Q000096:biosynthesis* / Q000235:genetics; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D018485:Muscle Fibers, Skeletal / Q000648:ultrastructure*; D009124:Muscle Proteins / Q000096:biosynthesis; D018482:Muscle, Skeletal / Q000378:metabolism*; D009929:Organ Size / Q000502:physiology; D012313:RNA / Q000096:biosynthesis / Q000235:genetics
D018971:Insulin-Like Growth Factor Binding Protein 2; D009124:Muscle Proteins; D012313:RNA; D004247:DNA; D003402:Creatine Kinase